Potential Role of Mic60/Mitofilin in Parkinson’s Disease

por Van Laar, Victor S., Otero, P. Anthony, Hastings, Teresa G., Berman, Sarah B.
Publicado 2019

P973: REAL-WORLD STUDY ON ADOPTION OF STANDARD OF CARE (SOC) FOR FRONTLINE TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA (FLTEMM) PATIENTS BETWEEN 2017 AND 2020/2021 ACROSS FRANCE, GERMANY,...

por Weisel, K., Wadlund, A., Gungor, G., Dergarabetian, E., Pacheco, C., Masurkar, N., Rodriguez-Otero, P.
Publicado 2022

Expansion of CD8+CD57+ T Cells in an Immunocompetent Patient with Acute Toxoplasmosis

por García-Muñoz, R., Rodríguez-Otero, P., Galar, A., Merino, J., Beunza, J. J., Páramo, J. A., Lecumberri, R.
Publicado 2009

P21: SUBSEQUENT ANTI-MYELOMA THERAPY AFTER IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) TREATMENT IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE KARMMA STUDY

por Rodríguez-Otero, P, San-Miguel, J, Anderson, LD, Lonial, S, Truppel-Hartmann, A, Sanford, J, Rowe, E, Campbell, TB, Munshi, N
Publicado 2022

Maternal fructose intake reinforces the effects of a Western-type diet in promoting SARS-CoV-2 cell entry factors in male offspring

por Donis, C., Fauste, E., Pérez, M., Rodríguez, L., Rodrigo, S., Álvarez-Millán, J.J., Otero, P., Panadero, M.I., Bocos, C.
Publicado 2022

P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYEL...

por Rodríguez-Otero, P, Shah, N, Munshi, N, Berdeja, J, Jagannath, S, Finney, O, Martin, N, Agarwal, A, Rowe, E, Campbell, T, San-Miguel, J
Publicado 2022

PINK1 Interacts with VCP/p97 and Activates PKA to Promote NSFL1C/p47 Phosphorylation and Dendritic Arborization in Neurons

por Wang, Kent Z. Q., Steer, Erin, Otero, P. Anthony, Bateman, Nicholas W., Cheng, Mary Hongying, Scott, Ana Ligia, Wu, Christine, Bahar, Ivet, Shih, Yu-Tzu, Hsueh, Yi-Ping, Chu, Charleen T.
Publicado 2018

P1463: PHASE I DOSE ESCALATION OF LAVA-051, A NOVEL BISPECIFIC GAMMA-DELTA T-CELL ENGAGER (GAMMABODY™), IN RELAPSED/REFRACTORY HEMATOLOGICAL MALIGNANCIES

por Broijl, A., van de Donk, N., Bosch, F., Mateos, M. V., Rodriguez-Otero, P., Tucci, A., Ghia, P., Adang, A., Parren, P., Tuinhof, I., Umarale, S., Winograd, B., van der Vliet, H., Kater, A.
Publicado 2022

P949: A PHASE 2 TRIAL OF ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: INITIAL SAFETY RESULTS FOR...

por Lesokhin, A. M., Arnulf, B., Niesvizky, R., Mohty, M., Bahlis, N. J., Tomasson, M. H., Rodrίguez-Otero, P., Quach, H., Raje, N. S., Iida, S., Raab, M.-S., Czibere, A., Sullivan, S., Leip, E., Viqueira, A., Leleu, X.
Publicado 2022

P10: TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED PHASE 1 RE...

por van de Donk, N. W. C. J, Minnema, M C, Berdeja, J G, Oriol, A, Krishnan, A, Rodríguez-Otero, P, Askari, E, Mateos, M, Costa, L. J, Verona, R, Ma, J, Girgis, S, Yang, S, Hilder, B. W, Russell, J, Goldberg, J. D, Chari, A
Publicado 2022

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP...

por Delforge, M., Usmani, S. Z., van de Donk, N. W., Garfall, A. L., Moreau, P., Oriol, A., Nooka, A. K., Rosinol, L., Bahlis, N., Rodriguez-Otero, P., Martin, T., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Krishnan, A.
Publicado 2022

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON

por Rosinol, L., Usmani, S. Z., Bahlis, N., Krishnan, A. Y., Nooka, A. K., Oriol, A., Delforge, M., Garfall, A. L., van de Donk, N. W., Rodríguez Otero, P., Martin, T. G., Diels, J., Van Sanden, S., Pei, L., Ammann, E., Kobos, R., Slavcev, M., Smit, J., Londhe, A., Moreau, P.
Publicado 2022

B08 IDECABTAGENE VICLEUCEL VERSUS STANDARD REGIMENS IN PATIENTS WITH TRIPLE-CLASS–EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA: KARMMA-3 A PHASE 3 RANDOMIZED CONTROLLED TRIAL...

por Rodríguez-Otero, P., Ailawadhi, S., Arnulf, B., Patel, K., Cavo, M., Nooka, A.K., Manier, S., Callander, N., Costa, L.J., Vij, R., Bahlis, N.J., Moreau, P., Solomon, S.R., Delforge, M., Berdeja, J., Truppel-Hartmann, A., Yang, Z., Favre-Kontula, L., Wu, F., Piasecki, J., Cook, M., Giralt, S.
Publicado 2023

P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

por Popat, R, Badros, A, Kumar, S, Rodriguez-Otero, P, Cohen, A, Manier, S, Voorhees, P, Gay, F, Rifkin, R, Martin, T, Chari, A, Weisel, K, Farooq, A, Jeng, B, Chng, W, Lee, H, Berdeja, J, Jadhav, V, Tosolini, A, Eliason, L, Palumbo, A, Dimopoulos, M, Lonial, S, Trudel, S, Richardson, P, Terpos, E
Publicado 2022

B04: COMBINATION OF SUBCUTANEOUS TECLISTAMAB WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1B MULTICOHORT STUDY

por Rodriguez-Otero, P, Dholaria, B, Askari, E, Reece, D, van de Donk, N, Chari, A, Goldschmidt, H, Krishnan, A, Martin, T, Mateos, M, Morillo, D, Rodriguez, C, Rosinol, L, San-Miguel, J, Balari, A, Wäsch, R, Weisel, K, Verona, R, Lin, S, Prior, T, Wade, M, Weiss, B, Goldberg, J, Oriol, A, Hari, P
Publicado 2022

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS

por Mateos, M, Hari, P, Bahlis, N, Chari, A, van de Donk, NWCJ, Dholaria, B, Garfall, AL, Goldschmidt, H, Kortüm, KM, Krishnan, A, Martin, T, Morillo, D, Oriol, A, Reece, D, Rodriguez, C, Rodríguez-Otero, P, San-Miguel, JF, Usmani, SZ, Verona, R, Lin, SXW, Prior, TJ, Wade, M, Weiss, B, Goldberg, JD, Askari, E
Publicado 2022

P42 HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA TREATED WITH TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISP...

por van de Donk, N., Rasche, L., Touzeau, C., Chari, A., Schinke, C., Minnema, M., Berdeja, J., Oriol, A., Rodriguez-Otero, P., Askari, E., Mateos, M., Costa, L., Caers, J., Krishnan, A., Vishwamitra, D., Ma, J., Qin, X., Gries, K.S., Kato, K., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J., Heuck, C., Moreau, P., San-Miguel, J.
Publicado 2023

P28 EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN PATIENTS WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER EXPOSURE TO NON-CELLULAR ANTI-B-CELL MATURATION ANTIGEN (B...

por van de Donk, N., Mateos, M.-V., Cohen, Y.C., Rodriguez-Otero, P., Paiva, B., Cohen, A.D., Martin, T., Suvannasankha, A., Madduri, D., Corsale, C., Schecter, J.M., De Braganca, K.C., Jackson, C.C., Varsos, H., Deraedt, W., Roccia, T., Mistry, P., Xu, X., Li, K., Zudaire, E., Akram, M., Pacaud, L., Avivi, I., San-Miguel, J.
Publicado 2023

P29 PHASE 1/2 RESULTS OF TALQUETAMAB, A G PROTEIN-COUPLED RECEPTOR FAMILY C GROUP 5 MEMBER D X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)...

por Minnema, M.C., Chari, A., Touzeau, C., Schinke, C., Berdeja, J., Oriol, A., van, de Donk N., Otero, P.R., Askari, E., Mateos, M.V., Costa, L.J., Caers, J., Rasche, L., Krishnan, A., Vishwamitra, D., Ma, X., Qin, X., Gries, K.S., Campagna, M., Masterson, T., Hilder, B., Tolbert, J., Renaud, T., Goldberg, J.D., Heuck, C., Miguel, J.S., Moreau, P.
Publicado 2023

Abnormal lipid processing but normal long-term repopulation potential of myc−/− hepatocytes

por Edmunds, Lia R., Otero, P. Anthony, Sharma, Lokendra, D'souza, Sonia, Dolezal, James M., David, Sherin, Lu, Jie, Lamm, Lauren, Basantani, Mahesh, Zhang, Pili, Sipula, Ian J., Li, Lucy, Zeng, Xuemei, Ding, Ying, Ding, Fei, Beck, Megan E., Vockley, Jerry, Monga, Satdarshan P. S., Kershaw, Erin E., O'Doherty, Robert M., Kratz, Lisa E., Yates, Nathan A., Goetzman, Eric P., Scott, Donald, Duncan, Andrew W., Prochownik, Edward V.
Publicado 2016